Claudio Scuoppo
Claudio Scuoppo
Research Scientist, Columbia University
Verified email at cumc.columbia.edu
TitleCited byYear
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity
Y Chien, C Scuoppo, X Wang, X Fang, B Balgley, JE Bolden, P Premsrirut, ...
Genes & development 25 (20), 2125-2136, 2011
4162011
A rapid and scalable system for studying gene function in mice using conditional RNA interference
PK Premsrirut, LE Dow, SY Kim, M Camiolo, CD Malone, C Miething, ...
Cell 145 (1), 145-158, 2011
2472011
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model
A Bric, C Miething, CU Bialucha, C Scuoppo, L Zender, A Krasnitz, Z Xuan, ...
Cancer cell 16 (4), 324-335, 2009
1742009
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
R Taulli, C Scuoppo, F Bersani, P Accornero, PE Forni, S Miretti, A Grinza, ...
Cancer research 66 (9), 4742-4749, 2006
1532006
High levels of Cre expression in neuronal progenitors cause defects in brain development leading to microencephaly and hydrocephaly
PE Forni, C Scuoppo, I Imayoshi, R Taulli, W Dastru, V Sala, UAK Betz, ...
Journal of Neuroscience 26 (37), 9593-9602, 2006
1352006
A tumour suppressor network relying on the polyamine–hypusine axis
C Scuoppo, C Miething, L Lindqvist, J Reyes, C Ruse, I Appelmann, ...
Nature 487 (7406), 244, 2012
1092012
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
Y Liu, C Chen, Z Xu, C Scuoppo, CD Rillahan, J Gao, B Spitzer, ...
Nature 531 (7595), 471, 2016
842016
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis
R Taulli, P Accornero, A Follenzi, T Mangano, A Morotti, C Scuoppo, ...
Cancer gene therapy 12 (5), 456, 2005
432005
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
G Fabbri, AB Holmes, M Viganotti, C Scuoppo, L Belver, D Herranz, ...
Proceedings of the National Academy of Sciences 114 (14), E2911-E2919, 2017
382017
PTEN action in leukaemia dictated by the tissue microenvironment
C Miething, C Scuoppo, B Bosbach, I Appelmann, J Nakitandwe, J Ma, ...
Nature 510 (7505), 402, 2014
332014
Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cells
S Chatterjee, L Seifried, ME Feigin, DL Gibbons, C Scuoppo, W Lin, ...
PloS one 7 (4), e34343, 2012
332012
Conditional activation of MET in differentiated skeletal muscle induces atrophy
T Crepaldi, F Bersani, C Scuoppo, P Accornero, C Prunotto, R Taulli, ...
Journal of biological chemistry 282 (9), 6812-6822, 2007
242007
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors
P Accornero, G Lattanzio, T Mangano, R Chiarle, R Taulli, F Bersani, ...
Clinical Cancer Research 14 (7), 2220-2226, 2008
202008
The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes
C Scuoppo, I Riess, M Schmitt-Ney, P Allegra, PE Forni, F Bersani, ...
Experimental cell research 313 (11), 2308-2317, 2007
172007
A CRISPR/Cas9 functional screen identifies rare tumor suppressors
A Katigbak, R Cencic, F Robert, P SÚnÚcha, C Scuoppo, J Pelletier
Scientific reports 6, 38968, 2016
162016
A common functional consequence of tumor-derived mutations within c-MYC
AA Chakraborty, C Scuoppo, S Dey, LR Thomas, SL Lorey, SW Lowe, ...
Oncogene 34 (18), 2406, 2015
162015
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity
S Marsilio, H Khiabanian, G Fabbri, S Vergani, C Scuoppo, E Montserrat, ...
Leukemia 32 (4), 1040, 2018
52018
Repurposing Dasatinib for Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma
C Scuoppo, W Jiguang, M Persaud, S Mittan, L Pasqualucci, R Rabadan, ...
Blood 130 (Suppl 1), 3843-3843, 2017
32017
Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma
SN Meyer, C Scuoppo, S Vlasevska, E Bal, AB Holmes, M Holloman, ...
Immunity, 2019
12019
Suppression of EZH2 accelerates MYC-driven lymphomagenesis by inhibition of apoptosis
I Appelmann, C Scuoppo, V Thapar, D Ledezma, A Lujambio, SW Lowe, ...
Blood 124 (21), 3009-3009, 2014
12014
The system can't perform the operation now. Try again later.
Articles 1–20